Expression and clinical significance of SNF5 in bladder cancer

Abstract

Objective To explore the expression and clinical significance of SNF5 in bladder cancer. Methods Based on the data from the Cancer Genome Atlas (TCGA) database, SNF5 mRNA level from 408 cases of bladder cancer tissues and 19 cases of normal bladder tissues were retrieved and analyzed with clinical data. Kaplan-Meier analysis was employed to study the relationship between SNF5 level and survival rate in these bladder cancer patients. qPCR was performed to determine the expression level of SNF5 in different bladder cancer cell lines (5637, T24, RT4, UM-UC-3, TCCSUP, J82) and normal human urothelial cell line SV-HUC-1. What's more, the protein expression of SNF5 in clinically collected bladder cancer samples (from 157 patients admitted in our hospital from January 2012 to December 2018) was detected by immunohistochemical (IHC) assay, and its association with clinicopathological features was analyzed with Cox regression analysis. Results The mRNA expression of SNF5 was higher in both bladder cancer tissues and cell lines than normal bladder tissues and cells, and the expression variations were significant among different subtypes of bladder cancer and cancer cell lines. The results of Kaplan-Meier analysis indicated that the patients with lower SNF5 mRNA level had worse prognosis than those with higher expression (P < 0.01). Cox regression analysis showed SNF5 was an independent prognostic factor for bladder cancer. The protein level of SNF5 was significantly correlated with myometrial infiltration (P < 0.01) and lymph node metastasis (P < 0.01). Conclusion SNF5 is upregulated in bladder cancer, and closely associated with its incidence, progression and prognosis. It may be used as a promising therapeutic target in treatment for bladder cancer.

Keywords

• snf5
• bladder cancer
• survival analysis